Biotech | April 12, 2022
Cambrex completes large-scale US API expansion
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Subscribe To Our Newsletter & Stay Updated
